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The administration of primary chemotherapy in breast cancer (BC)
patients permits in vivo assessment of tumour chemosensitivity
and evaluation of treatment-induced changes in tumour biology.
Although administered according to different schedules, primary
chemotherapy has repeatedly demonstrated it can be highly active
in downstaging BC, thus facilitating subsequent conservative
surgical approaches (Bonadonna, 1990; Mauriac et al, 1991;
Powles et al, 1995; Fisher et al, 1997; Makris et al, 1998). In addi-
tion, several courses of primary chemotherapy have been reported
to significantly inhibit tumour growth rate (Daidone et al, 1991;
Gardin et al, 1994). In contrast, neither c-erbB2 nor steroid
hormone receptor expression were consistently affected (Bottini 
et al, 2000; Frassoldati et al, 1997). 
Accordingly, reduction in tumour size and in proliferative
activity are so far considered the most relevant biological effects
of chemotherapy on primary BC. However, an association
between these 2 phenomena has not yet been determined. 
In the present study, we evaluated the variation in the number of
cells in the G1, S, G2 and M phases of the cell cycle by Ki67
immunostaining before and after chemotherapy in a series of BC
patients diagnosed and followed up in the same institution. The
primary aim of the study was to search for a relationship between
the decline in Ki67 stained cells induced by the treatment and the
clinical response. The secondary aims were: (1) to evaluate, either
by univariate or multivariate analysis, the role of both response to
treatment and Ki67 antigen expression (determined either at base-
line or at the end of the treatment) in predicting the disease relapse;
(2) to see whether changes in certain pre-treatment tumour charac-
teristics, i.e. histology grade, steroid hormone receptor, c-erbB2,
p53 and bcl2 expressions, before and after treatment, may be
related to the tumour shrinkage. 
MATERIALS AND METHODS 
Patients 
The study was carried out on 157 consecutive patients recruited in
our institution from August 1990 to January 1997 with an operable
breast tumour or locally advanced disease (T2-4N0-1M0). The
patients had been enrolled in 2 consecutive phase II studies that
aimed to evaluate the activity of the CMF regimen (cyclophos-
phamide, methotrexate, 5-fluorouracil) administered in associa-
tion with tamoxifen in cases with oestrogen receptor positive
(ER+) tumours, and that of the single agent epirubicin. None of the
patients had objective skin inflammation or oedema. On first
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presentation an incision biopsy was performed on each patient.
Initial staging comprised clinical examination, bilateral mammog-
raphy, echography, chest X-ray, liver echography or CT scan, bone
scintigraphy. All patients gave informed consent to the diagnostic
procedures and the proposed treatment. 
Treatment 
Chemotherapy was started within 1 or 2 days from diagnosis. The
first consecutive 76 patients received the CMF (cyclophos-
phamide, methotrexate and 5-fluorouracil) chemotherapy
regimen, which was given on days 1 and 8 every 28 days. The dose
of cyclophosphamide and 5-fluorouracil was 600 mg m–2 of body
surface area, and the dose of methotrexate was 40 mg m–2. The
subsequent 81 patients received epirubicin 60 mg m–2 on days 1
and 2 every 21 days. The first consecutive 45 patients, with
oestrogen positive (ER+) BC at first biopsy, received additional
tamoxifen (TAM) treatment (30 mg daily) in association with the
CMF treatment. TAM was administered after obtaining the results
of the receptor status, about 20 days from the first biopsy, and
continued up until surgery. Each month the size of the primary
tumour and the size of the axillary lymph-nodes, when appre-
ciable, were carefully measured with a calliper by the same clini-
cian. Response was assessed by the clinical measurement of the
changes in the product of the two largest diameters recorded in two
successive evaluations. According to the World Health
Organization (WHO) criteria (World Health Organisation, 1978)
tumour progression (PD) was defined as an increase of at least
25% in tumour size, stable disease (SD) as an increase of less than
25% or a reduction of less than 50%, partial response (PR) as a
tumour shrinkage greater than 50%, and complete response (CR)
as the complete disappearance of all clinical signs of disease. 
Surgery was planned after full clinical reassessment.
Quadrantectomy or modified radical mastectomy were performed
when indicated in association with full axillary dissection. All
patients subjected to quadrantectomy underwent irradiation of the
residual breast (60 Gy delivered over 6 weeks). 
Histopathologic grade and immunohistochemistry 
The degree of malignancy was assessed according to the Elston
and Ellis grading system which classifies tumours into grade I
(well differentiated), grade II (moderately differentiated), and
grade III (poorly differentiated) (Elston and Ellis, 1991). 
The immunohistochemical assays used in this study are fully
described elsewhere (Bottini et al, 2000). Briefly, an antigen
retrieval step was performed by heating a tissue section in a citrate
buffer. The primary antibodies applied were: ER [mouse mono-
clonal 6F11 (Novocastra Lab, Newcastle upon Tyne, UK), dilution
1:50, 1 h incubation at RT]; PgR [mouse monoclonal 1A6
(Novocastra Lab), dilution 1:20, 1 h incubation at RT]; Ki67 [mouse
monoclonal Mib-1 (Dako, Glostrup, Denmark), dilution 1:30, 1 h
incubation at RT]; p53 [mouse monoclonal D07 (Novocastra Lab),
dilution 1:100, 1 h incubation at RT]; bcl-2 [mouse monoclonal 124
(Dako), dilution 1:40, overnight at 4˚C]; c-erbB2 [mouse mono-
clonal CB11 (Novocastra Lab), overnight at 4˚C]. 
Biotinylated horse anti-mouse IgG and avidin–biotin–peroxi-
dase complex were applied as a staining method (Vectastatin ABC
kit; Vector Laboratories, Inc, Burlingame, CA). A solution
containing hydrogen peroxide (0.06% v/v) and diamino-benzidine
4 HCL (DAB; 0.05 v/v) was used as chromogen. 
Immunohistochemical scoring 
All samples had a negative control slide (no primary antibody) of
an adjacent section to assess the degree of non-specific staining.
Positive controls included breast carcinomas known to exhibit
high levels of each marker. 
All staining was scored by counting the number of positive
stained cells and expressed as a percentage of the total tumour
cells (at least 1000) counted across several representative fields of
the section using a standard light microscope equipped with a
10 × 10 square graticule. Reproducibility of counting was assessed
by a second investigator re-scoring 10 slides. 
The relative intensity of ER and PgR staining was assessed in a
semi-quantitative fashion as previously described by McCarty et al
(1985), incorporating both the intensity and distribution of specific
staining. A value (HSCORE) was derived from the sum of the
percentages of positive-stained epithelial cells multiplied by the
weighted intensity of staining. Specimens were deemed receptor
positive if the HSCORE was greater than 100 (Robertson et al,
1992). For the other biological parameters, a cut-off of ≥ 5 positive
cells was introduced to discriminate p53-positive and p53-
negative primary malignancies, as previously reported (Silvestrini
et al, 1993), while no cut-offs were introduced for c-erbB2 and
bcl2 expression. The immunohistochemical evaluation at mastec-
tomy was performed by the same pathologists who remained
blinded to the disease response and the score assessed at first biopsy.
Statistical analysis 
Ki67 staining was analysed both as a continuous variable and after
categorisation into 3 classes (≤ 10%, 11–29%, ≥ 30%). 
Non-parametric statistical methods (Mann–Whitney test for
unpaired data, Wilcoxon’s matched-pairs signed-rank test 
for paired data, Spearman rho for simple correlation analysis) were
used in the primary analyses of the data. Multiple group compar-
ison for Ki67 expression at baseline was performed by ANOVA.
In order to take into account a possible confounding effect of base-
line Ki67, ANCOVA was performed instead of ANOVA for
multiple group comparison when considering the reduction in
Ki67 expression and Ki67 staining at residual tumours.
Associations among the variables were evaluated by the χ 2 test.
Multivariate analysis was performed by multiple linear regression.
As the variable residual Ki67 after chemotherapy was not
normally distributed, a square root transformation of this variable
was used in the multiple regression and ANCOVA analyses.
Relapse-free survival (RFS) was calculated from diagnosis to the
occurrence of relapse of disease. The Cox model was employed to
perform multivariate survival analysis for the prediction of disease
recurrence. Statistical analysis was performed on an IBM-compatible
personal computer using the Statistica for Windows (1995) software
package. 
RESULTS 
Patient characteristics at diagnosis are shown in Table 1. Most
patients (75%) had infiltrating ductal carcinoma; infiltrating
lobular carcinoma and mixed forms (infiltrating ductal + lobular)
were found in 19% and 6%, respectively. 
Figure 1 shows how baseline Ki67 expression correlated
directly with ER and bcl2 expression but negatively with both c-
erbB2 and p53 immunostaining. G3 tumours had higher Ki671108 A Bottini et al
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expression (median 16 (0–90)) than G2 (median 13 (1–55)),
although the difference failed to attain statistical significance
(P < 0.07). No significant association was observed between Ki67
expression and either tumour size (median 16 (0–50) and 16
(1–90) for T2 vs T3–4 tumours) or lymph node status (median 14.5
(1–50) and 16 (0–90) for N+ vs N– BC). 
Treatment activity 
A median of 3 cycles was administered (range 3–5). 156 patients
completed the chemotherapy treatment and were evaluable for
response. One patient refused to continue the treatment plan at the
end of the first cycle. 37 patients attained clinical CR (23.7%), 76
clinical PR (48.7%) for an overall response rate (CR + PR) of
72.4%, 40 patients showed SD (25.6%), while only 3 progressed
(1.9%). Only 4 patients (2.6%) attained pathological complete
remission, 2 of them with clinical CR and 2 with clinical PR. 
According to the treatment administered, the distribution of CR,
PR, SD and PD was 21/76 (27.6%), 39/76 (51.3%), 14/76 (18.4%)
and 2/76 (2.6%) for the patients submitted to CMF + TAM and
16/80 (20.0%), 37/80 (46.2%), 26/80 (32.5%) and 1/80 (1.3%) for
those receiving the single agent epirubicin. 
No statistically significant differences in response rates were
found according to the pre-treatment Ki67 expression: 39/51
(76.5%), 57/83 (68.7%), and 17/23 (73.9%) overall response rates
were found in tumours with ≤ 10% Ki67 positive cells, between
11% and 29% and ≥ 30%, respectively (P = 0.67); while the corre-
sponding complete response rates were 16/51 (31.3%), 16/83
(19.3%) and 5/23 (21.7%), respectively (P = 0.28). Responses
were equally distributed in c-erbB2-positive and -negative
tumours in both the CMF+TAM subgroup and in the epirubicin
subset. 
All patients received radical surgery. Modified mastectomy was
performed in 68 cases (43.6%) and quadrantectomy followed by
radiation therapy in 88 (56.4%). 
Effect of chemotherapy +/– endocrine therapy on Ki67
staining 
A total of 152 BC had Ki67 assessed before and after
chemotherapy Ki67 was not assessable at mastectomy in 4 tumour
samples due to pathological complete remission. The median
number of cells per tumour expressing the Ki67 antigen fell from
16% (range: 0–90%) at the initial biopsy to 8% (range: 0–80%) at
mastectomy (P < 0.001). At the end of the course of chemotherapy,
101 residual tumours (65.6%) had <10% Ki67 positive cells, 43
(27.9%) between 10% and 29%, 10 (6.5%) ≥ 30%. A moderate but
highly significant relationship was found between Ki67 values
before chemotherapy and those evaluated afterwards (Spearman
r = 0.49, P < 0.001). 
Figure 2C shows that Ki67 reduction was greater in patients
who attained a clinical response than in non-responders. Ki67
expression at baseline was not different between patients who
subsequently did or did not respond to treatment (Figure. 2A),
whereas Ki67 evaluated at residual tumours after chemotherapy
was lower in patients with complete response than in those with
partial response or no change (Figure. 2B). 
No significant difference in reduction in Ki67 expression was
found in patients receiving CMF + TAM (mean: –7.34 ± SD 10.8)
vs those submitted to epirubicin (mean –6.61 ± SD 14.2). 
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Figure 1 Box and whisker plots of baseline distribution of Ki67% expression according to oestrogen receptors, c-erbB2, p53 and bcl-2 status. Data 
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Effect of cytotoxic treatment on histology grade,
steroid hormone receptor status, p53, bcl2 and c-erbB2
expression 
Oestrogen receptor expression at baseline decreased after
chemotherapy in 57 specimens (37.8%), increased in 55 (36.4%),
and remained unchanged in 39 (25.8%). The corresponding
pattern for PgR was 52 (35.9%), 41 (28.2%), and 52 (35.9%),
respectively. Histology grade was only minimally affected by the
treatment, being unchanged in 138 specimens (93.2%), increased
in 7 (4.8%) and decreased in 3 (2.0%). As regards p53 and bcl2
expression, it rose in 30 (21.4%) and 24 (17.5%) specimens after
treatment, decreased in 17 (12.1%) and 20 (14.6%), and remained
unchanged in 93 (66.5%) and 93 (67.9%), respectively. Finally, c-
erbB2 immunostaining showed an increase from baseline in 18
specimens (12.9%), a decrease in 4 (2.9%) and no change in 117
(84.2%). 
When these variables were considered as dichotomous (positive
and negative), the changes after treatment were found to be even
less evident. PgR-positive tumours before chemo-endocrine
therapy administration became negative in 21.5% of cases,
whereas the opposite pattern occurred in 15.2%. The other biolog-
ical parameters did not change their baseline status in more than
10% of cases. 
Multivariate analysis of independent variables
associated with clinical response 
A multivariate logistic analysis was performed in order to search
for clinical and biological parameters assessed at baseline as
predictors for clinical response. Treatment, CMF + TAM vs epiru-
bicin (P = 0.005), and postoperative pathologic lymph node status
(P = 0.05) were the only variables associated with overall
response. Tumour size, baseline clinical lymph node status,
histology grade, KI67, c-erbB2, p53, bcl2, ER, PgR immuno-
staining and menopausal status did not enter the model. 
When considering the changes in the biological parameters
before and after treatment, reduction in Ki67 expression (P = 0.02)
and treatment (P = 0.05) were independently associated with
tumour shrinkage (complete + partial response), whereas the
changes in c-erbB2, p53, bcl2 and steroid hormone receptor
immunostaining did not enter the model (data not shown). 
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Table 1 Patient characteristics 
No. 157 
Age 
Median 56 
Range 26–71 
Menopausal status 
Premenopause 54  (34.4%) 
Postmenopause 103  (65.6%) 
TNM 
T2 110 (70.1%) 
T3 33 (21%) 
T4 14 (8.9%) 
N0 83 (52.9%) 
N1 74 (47.1%) 
Grade 
II 54  (34.4%) 
III 103  (65.6%) 
Receptor status 
ER +a 114 (72.6%) 
ER – 43  (27.4%) 
PgR +a 64 (41.6%) 
PgR – 90  (58.4%) 
N.E.b 3 
Ki67 
≤ 10% 51  (32.5%) 
11–29% 83  (52.9%) 
≥ 30% 23  (14.6%) 
c-erbB2 
Positive 38  (26.2%) 
Negative 107  (73.8%) 
N.E.b 12 
P53 
positive 41  (28.7%) 
negative 102  (71.3%) 
N.E.b 14 
bcl-2 
positive 106  (75.2%) 
negative 35  (24.8%) 
N.E.b 16 
aER+ (HSCORE > 100); PgR+ (HSCORE > 100). bNot evaluable. A cut off of
5% stained cells was introduced for defining p53 positive tumours, whereas
no cut off was introduced for c-erbB2 and bcl2 staining. 1110 A Bottini et al
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Multivariate analysis of independent variables
associated with reduction in Ki67 expression and Ki67
immunostaining in residual tumour 
C-erbB2 expression was the only variable inversely associated
with Ki67 reduction, whereas bcl-2 was the only directly associated
independent variable (Table 2). Ki67 expression in residual
tumour was directly associated with p53 at baseline, whereas
pretreatment ER positivity was inversely associated (Table 2). 
Relapse-free survival according to clinical and
biological variables 
After a median follow-up of 52.7 months, 40 patients (25.5%)
progressed and 25 (15.9%) died of disease. Patients attaining a
complete clinical response showed a significantly longer RFS than
those showing partial or no response (P < 0.05). A non-significant
increased risk of recurrence was seen among patients with elevated
Ki67 at baseline (Figure 3A). Conversely, a significant difference
in RFS was observed when Ki67 expression at residual tumours
was considered (Figure 3B). 
When clinical response to treatment, menopausal status,
histology grade, c-erbB2, bcl2, p53, steroid hormone receptor
status, treatment administered, chemotherapy-induced Ki67 
reduction, tumour dimension and lymph node status (evaluated
clinically before treatment and pathologically afterwards) were
considered together in a multivariate regression Cox model, clin-
ical response (P < 0.03), tumour size (P < 0.03) and progesterone
receptor status (P < 0.02) were independent predictors for disease
recurrence, whereas postoperative lymph node status just failed to
enter the model (P = 0.07). 
DISCUSSION 
In this single institution experience involving a relatively large
number of patients with operable breast cancer, our finding that
chemotherapy is able to induce a reduction in the number of cells
in the cell cycle confirms previous data (Daidone et al, 1991;
Gardin et al, 1994; Frassoldati et al, 1997; Chang et al, 1999).
Chemotherapy-induced reduction in Ki67 expression was found to
be significantly associated with tumour shrinkage by both
univariate and multivariate analysis. The latter finding is consis-
tent with the notion that the antiproliferative effect of the cytotoxic
agents is a mechanism of antitumour activity (Daidone et al, 1991;
Change et al, 1999). 
The patients in the present study were consecutively submitted
to 2 different treatments, which led to a slight difference in the
response rate. This may represent a limitation of our study.
Another limitation is that tamoxifen has been found to have
antiproliferative activity (Osborne et al, 1983; Clarke et al, 1993).
As tamoxifen was added to chemotherapy in the first 76 cases, it is
impossible in our study to ascertain the contribution the drug may
have had in reducing the Ki67 expression. In order to avoid
possible biases, the treatment was included among the independent
variables in the multivariate analyses. 
Table 2 Independent variables associated with reduction in %Ki67 immunostaining or %Ki67 at residual
tumours according to multivariate regression analysis 
Ki67 reduction 
B SE  B  P
Tumour sizea 0.88 1.84 0.63 
Baseline lymph node statusa,b 0.04 2.27 0.98 
Post-chem lymph node statusa,c –1.00 2.38 0.67 
Histology gradea 0.78 2.69 0.77 
c-erbB2  –6.80 2.81 <0.02
p53a 2.09 2.60 0.42 
bcl2 6.06  3.00  <0.04 
ERa 5.63 3.11 0.07 
PgRa 1.62 2.67 0.54 
Menopausea –0.85 2.48 0.73 
Treatmenta –2.27 2.32 0.33 
(CMF + TAM vs epirubicin) 
Ki67 expression at residual tumours 
Tumour sizea 1.00 1.50 0.50 
Baseline lymph node statusa,b 1.85 1.70 0.28 
Post-chem lymph node statusa,c –1.69 1.90 0.37 
Histology gradea 0.92 2.15 0.67 
c-erbB2a –0.23 2.30 0.92 
p53 5.02  2.09  <0.02 
bcl2a –4.72 2.46 0.06 
ER  –9.54 2.45 <0.001
PgRa –0.80 2.19 0.72 
Menopausea –0.04 2.01 0.98 
Treatment 5.68  1.86  <0.002 
(CMF + TAM vs epirubicin)
aNot included in the model. bPreoperative clinical lymph node status. cPost operative pathologic lymph node
status. B = Estimated regression coefficient. S.E. = Standard Error of B. P = The significant level of the Wald
statistics. Primary chemotherapy-induced Ki67 reduction in breast cancer 1111
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Two baseline markers, bcl2 and c-erbB2, in multivariate
analysis were directly and inversely associated with a reduction in
Ki67 expression, respectively. It has been shown that bcl2 is a
marker of tumour responsiveness to endocrine therapy (Elledge 
et al, 1997). Therefore, the association of tamoxifen with
chemotherapy in a number of patients may have contributed to
the relationship between the reduction in Ki67 expression and
pretreatment bcl2 immunostaining. The independent negative
relationship between c-erbB2 expression and reduction in Ki67
suggests a blockade of the antiproliferative effect of chemo-
endocrine therapy in c-erbB2-positive tumours. However, a
possible concomitant antiapoptotic effect of c-erbB2 expression
(Hamilton and Piccart, 2000) could not be excluded by our data. 
Pretreatment Ki67 immunostaining showed a moderate but
significant correlation with the antigen expression at mastectomy
(or quadrantectomy). In other words, patients with rapidly prolif-
erating BC before chemotherapy had a greater chance of main-
taining elevated cell kinetic activity after treatment. In this sense, 2
baseline biological parameters, ER and p53, which correlated with
low and elevated pre-chemotherapy Ki67 staining respectively,
were also associated with Ki67 expression at the residual tumour.
The relationship between Ki67 expression before and after treat-
ment and the scarce influence of chemotherapy on p53, bcl2 and
steroid hormone receptor status suggest that cytotoxic treatment
reduces tumour size but has a limited effect on intrinsic tumour
aggressiveness. Our findings are also consistent with the general
concept that tumours with elevated proliferative activity usually
have a poor prognosis in spite of a similar or even better response
to the treatment administered (Gardin et al, 1994; Silvestrini et al,
1995; Bonetti et al, 1996). 
Ki67 expression at first biopsy showed only a weak, inverse
correlation with RFS; conversely, this inverse relationship attained
statistical significance when Ki67 was evaluated at the end of
treatment. 
The implication is that the residual tumour is resistant to
chemotherapy and that the proliferative activity assessed at 
this time has a greater value in predicting disease recurrence
compared with baseline assessment. This observation may have
direct clinical implications, because elevated proliferative activity
in residual tumour suggests the persistence of aggressive disease
and the need for subsequent adjuvant treatment possibly with non-
cross-resistant schemes. 
Patients whose breast cancers over-expressed c-erbB2 had
similar response rates to either CMF + TAM or epirubicin, unlike
the patients whose primary malignancy did not over-express c-
erbB2. The latter finding seems to contrast with the data from the
literature which indicate a role of c-erbB2 status in predicting the
efficacy of both CMF and tamoxifen. Most of the published data
refer to CMF or tamoxifen administered alone (Pegram et al, 1998;
Hamilton and Piccart, 2000), but few data are available on the
association of the 2 drugs. A comparative study in an adjuvant
setting showed that c-erbB2 expression retained prognostic signif-
icance in the subgroups treated with CMF or tamoxifen but not in
the group that received both drugs (Tetu and Brisson, 1994). Our
results are consistent with this study. Even so, we cannot exclude
the possibility of a type II error due to the small number of cases
submitted to CMF + TAM. 
In our series, clinical response was associated with a reduction in
Ki67 expression, but changes in p53, c-erbB2, bcl2 and steroid
hormone receptor status did not contribute to the treatment activity.
It should be noted that the changes in Ki67 expression seen in the
present study are relatively small, so that the treatment-induced
tumour shrinkage is to be ascribed to either reduced proliferative
activity and/or to increased apoptosis. The relationship between
clinical response and reduction in Ki67 expression was already
found in a previous neoadjuvant study with the chemo-endocrine
regimen of mitoxantrone, methotrexate, mitomycin and tamoxifen
(Chang et al, 1999). In contrast with our results, in this study clin-
ical response, defined as complete response or minimal residual
disease, was also associated with an increase of both PgR and bcl2
expression. Differences in cytotoxic drug administration, percent of
patients who received tamoxifen (less than 50% in our study vs
100% in the Chang et al study) and response criteria adopted may
account for the discrepancies observed.
One of the possible advantages in administering primary
chemotherapy over adjuvant chemotherapy is that it allows the
identification of surrogate parameters of treatment efficacy (Fisher
and Mamounas, 1995). In our study the clinical response was
significantly correlated with greater disease-free survival, thus
confirming previous experiences (Bonadonna et al, 1998; Fisher 
et al, 1998). This correlation suggests that breast tumour response
might be used as an indicator of the response of micrometastases
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to the therapy; however, this use needs to be formally validated in
randomised clinical trials. 
When multivariate survival analysis was performed to search
for independent variables predicting for disease recurrence,
tumour response but not Ki67 changes entered the Cox model. As
previously discussed, reduction in kinetic cell activity is one way
to achieve tumour shrinkage. For this reason it fails as an indepen-
dent predictor of RFS when considered together with tumour
response. 
In conclusion, the administration of primary chemotherapy to
breast cancer patients could offer clinical and biological advan-
tages over adjuvant chemotherapy. It allows the clinician to better
understand the mechanisms of the treatment activity and may
provide surrogate parameters of treatment efficacy (Fisher et al,
1998). In this respect, we showed that chemo-endocrine therapy is
able to induce tumour shrinkage and reduction in Ki67-stained
cells, but its effect on tumour biology/aggressiveness is minimal.
Reduction in the number of cells in the cell cycle correlates with
tumour response but fails to be an independent predictor for RFS.
This suggests that it is a mechanism of disease response. Ki67
expression after treatment was found to be a better predictor for
disease relapse than the antigen expression at baseline. 
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